Navigation Links
Regeneron's Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentech's Lucentis
Date:8/15/2013

EXTON, Penn., Aug. 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed retinal specialists/general ophthalmologists now treat 26 percent of their intravitreal pharmaceutically treated wet age-related macular degeneration (AMD) patients with Regeneron's Eylea, a significant increase from one year ago. Eylea has been on the market since November 2011. In fact, patient share for Eylea now surpasses that for Roche/Genentech's Lucentis (21 percent), which has been available since 2006. However, off-label use of Roche/Genentech's Avastin continues to dominate the wet AMD market, largely due to its low cost relative to the other anti-vascular endothelial growth factor (VEGF) agents and proven efficacy.

According to the TreatmentTrends®: Dry/Wet AMD (US) report, physician preference for Eylea is likely driven by its convenient twice monthly dosing frequency, which is supported by the finding that wet AMD patients receive significantly fewer Eylea injections than Avastin or Lucentis injections during the first two years of treatment. Data from the report also suggest that Eylea is moving up in the wet AMD treatment algorithm and is now the most preferred branded therapy indicated for the treatment of wet AMD, with Lucentis being the typical third-line treatment option.

"This shift in Eylea use is likely motivated by prescribers' high satisfaction with the agent and their positive perceptions related to its efficacy," said BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D. "These perceptions will contribute to the continued growth of Eylea patient share over the next six months and will trail only Avastin's patient share."

Report findings also reveal that surveyed physicians rate geographic atrophy associated with dry AMD as the AMD disease type with the greatest need for new products, a finding which is not surprising given the high degree of vision loss suffered by these patients and the paucity of treatment options currently available for dry AMD. However, even as physicians acknowledge the high unmet need for dry AMD, few are aware of products in development for dry AMD, including Otsuka/Acucela's ACU-4429 and MacuCLEAR's MC-1101. Instead, awareness is higher for surveyed products in development for wet AMD, in particular Ophthotech's Fovista, Ohr Pharmaceuticals's squalamine and Allergan's anti-VEGF DARPin. Surveyed physicians perceive these products for wet AMD as having potential to provide the most value to the treatment of their AMD patients, largely due to Fovista's synergistic effect when administered with an anti-VEGF agent, squalamine's eye drop formulation and anti-VEGF DARPin's novel mechanism of action and duration of action.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Watching, Reading and Listening: A New Way to Interact with Patient Information
5. Phreesia identifies over 26% of patients who require additional autism evaluation
6. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
10. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
11. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):